AbbVie (NYSE:ABBV) Earns “Outperform” Rating from Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reiterated by Royal Bank Of Canada in a note issued to investors on Tuesday, Benzinga reports. They currently have a $280.00 price target on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 1.88% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company boosted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Scotiabank raised their price target on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Guggenheim reiterated a “buy” rating and set a $288.00 price objective on shares of AbbVie in a research note on Friday. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Finally, Piper Sandler boosted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Stock Down 2.2%

Shares of AbbVie stock traded down $6.30 during trading on Tuesday, reaching $274.82. The company’s stock had a trading volume of 6,408,343 shares, compared to its average volume of 6,414,627. The company has a market cap of $485.55 billion, a price-to-earnings ratio of 77.63, a P/E/G ratio of 1.26 and a beta of 0.24. AbbVie has a 1-year low of $190.75 and a 1-year high of $283.43. The company has a 50-day simple moving average of $259.79 and a two-hundred day simple moving average of $237.39.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company posted $2.97 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie will post 13.94 earnings per share for the current year.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Institutional Trading of AbbVie

A number of hedge funds have recently modified their holdings of the stock. First County Bank CT grew its holdings in AbbVie by 0.4% during the third quarter. First County Bank CT now owns 14,671 shares of the company’s stock worth $3,838,000 after acquiring an additional 61 shares during the period. Sage Capital Advisors llc raised its position in AbbVie by 0.4% during the third quarter. Sage Capital Advisors llc now owns 23,552 shares of the company’s stock valued at $6,161,000 after acquiring an additional 96 shares in the last quarter. McGlone Suttner Wealth Management Inc. lifted its holdings in AbbVie by 0.6% in the third quarter. McGlone Suttner Wealth Management Inc. now owns 12,230 shares of the company’s stock valued at $3,199,000 after acquiring an additional 70 shares during the period. Sivik Global Healthcare LLC lifted its holdings in AbbVie by 46.7% in the third quarter. Sivik Global Healthcare LLC now owns 22,000 shares of the company’s stock valued at $5,755,000 after acquiring an additional 7,000 shares during the period. Finally, Compass Financial Group INC SD boosted its position in AbbVie by 15.3% in the 3rd quarter. Compass Financial Group INC SD now owns 1,648 shares of the company’s stock worth $431,000 after purchasing an additional 219 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential third-quarter revenue beat: RBC expects AbbVie to exceed top-line estimates, driven by continued momentum in Skyrizi, Rinvoq and Vraylar. The outlook reinforces the company’s ability to offset ongoing Humira erosion ahead of its quarterly results. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could support broader use of the therapy and strengthen AbbVie’s post-Humira growth strategy. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and franchise expansion: Recent Skyrizi and Rinvoq data presented at ACG 2026, along with new oncology designations and early metabolic-program results, are broadening the investment case beyond immunology. Analysts also point to a recently completed acquisition and a fresh FDA approval as potential future growth drivers. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings
• Positive Sentiment: Analyst support: Royal Bank of Canada reaffirmed its “Outperform” rating and set a $280 price target, while broader commentary describes AbbVie’s pipeline as potentially undervalued. The stock also remains attractive to income-focused investors because of its dividend profile. RBC Reaffirms AbbVie Outperform Rating
• Neutral Sentiment: Investor debate continues: Comparisons with Eli Lilly highlight AbbVie’s steadier diversification through Skyrizi and Rinvoq versus Lilly’s faster cardiometabolic growth, leaving investors divided over relative upside.
• Negative Sentiment: Key risks remain: Humira sales continue to decline, immunology competition is increasing, and AbbVie’s elevated valuation leaves less room for disappointing results or weaker guidance.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.